Virax Biolabs Group Limited Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Accounts payable and accrued liabilities

Accounts payable and accrued liabilities

12 Months Ended

Mar. 31, 2025

Subclassifications of assets, liabilities and equities [abstract]

Accounts payable and accrued liabilities

Note 11 — Accounts payable and accrued liabilities


	As of March 31,
	2025		2024
Accounts payable	$	56,093	$	45,631
Accrued bonuses		60,485		—
Accrued payroll taxes		7,049		12,143
Accrued liabilities		126,543		63,120
Total accounts payable and accrued liabilities	$	250,170	$	120,894

Amounts included in accounts payables

Accounts payable for the year ended March 31, 2025 consists mostly of routine operating costs. Accrued liabilities for the year ended March 31, 2025 consists mainly of unpaid directors and officers insurance and accrued professional services. Accounts payable and accrued liabilities for the year ended March 31, 2024 consisted mainly of professional fees, legal fees and consulting services to various vendors.